CEBPA double‐mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis

No abstract is available for this paper.

• Publication year

  2013

• Venue

  British Journal of Haematology

• Publication date

  2013-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bjh.12297PMID 23521373
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis

  2013cited by this paper
• Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis

  2012cited by this paper
• A novel hierarchical prognostic model of AML solely based on molecular mutations.

  2012influential reference
• GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.

  2012cited by this paper
• Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study.

  2011cited by this paper
• An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling

  2011cited by this paper
• Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.

  2011cited by this paper
• Strikingly different molecular relapse kinetics in NPM 1 c , PML-RARA , RUNX 1-RUNX 1 T 1 , and CBFB-MYH 11 acute myeloid leukemias

  2010cited by this paper
• Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

  2010cited by this paper
• Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias.

  2010cited by this paper
• Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.

  2010cited by this paper
• Robust and Sensitive Detection of Insertions, Deletions and Point Mutations In CEBPA, a GC-Rich Content Gene, Using 454 Next-Generation Deep-Sequencing (NGS).

  2010cited by this paper
• Poor prognosis in familial acute myeloid leukaemia with combined biallelic CEBPA mutations and downstream events affecting the ATM, FLT3 and CDX2 genes

  2010influential reference
• The Role of Different Genetic Subtypes In CEBPA Mutated AML

  2010cited by this paper
• Dysregulation of the C/EBPalpha differentiation pathway in human cancer.

  2009cited by this paper
• Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

  2009influential reference
• Complexity of CEBPA Dysregulation in Human Acute Myeloid Leukemia

  2009influential reference
• Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis

  2009influential reference
• An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase

  2008cited by this paper
• Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

  2008cited by this paper
• Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.

  2008cited by this paper
• Intraplatform reproducibility and technical precision of gene expression profiling in 4 laboratories investigating 160 leukemia samples: the DACH study.

  2008cited by this paper
• Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia

  2005cited by this paper
• Risk Assessment in Patients with Acute Myeloid Leukemia and a Normal Karyotype

  2005cited by this paper
• CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.

  2004cited by this paper
• Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein a in myelodysplastic syndromes and acute myeloid leukemias

  2002cited by this paper
• Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias.

  2002cited by this paper
• Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.

  1999cited by this paper
• Brief Report Results and Discussion

  year unknowninfluential reference

• CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment

  2024influential citation
• Prognostic impact of CEBPA mutational subgroups in adult AML

  2024cites this paper
• Impact of different CEBPA mutations on therapeutic outcome in acute myeloid leukemia

  2024cites this paper
• Prognostic significance of GATA2 in patients with MDS/AML: a systematic review and meta-analysis

  2024cites this paper
• TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression

  2023influential citation
• Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations

  2023cites this paper
• Computational modeling of methylation impact of AML drivers reveals new pathways and refines AML risk-stratification

  2023cites this paper
• Acute Myeloid Leukemia With CEBPA Mutations: Current Progress and Future Directions

  2022cites this paper
• 基于CSF3R突变与治疗后微小残留病对CEBPA双突变急性髓系白血病预后再分层研究

  2022cites this paper
• Acquired somatic variants confirm the independent development of AML in monozygotic twins with germline CEBPA variant.

  2022cites this paper
• Mutational Landscape of CEBPA in Mexican Pediatric Acute Myeloid Leukemia Patients: Prognostic Implications

  2022influential citation
• Companion gene mutations and their clinical significance in AML with double or single mutant CEBPA

  2022cites this paper
• Laboratory evaluation and prognostication among adults and children with CEBPA‐mutant acute myeloid leukemia

  2021cites this paper
• The clinical characteristics and prognosis of cytogenetically normal AML with single mutations of CEBPA

  2021cites this paper
• Novel insights of acute myeloid leukemia with CEBPA deregulation: heterogeneity dissection and re-stratification.

  2021cites this paper
• Risk Stratification of Cytogenetically Normal Acute Myeloid Leukemia With Biallelic CEBPA Mutations Based on a Multi-Gene Panel and Nomogram Model

  2021cites this paper
• Prognostic Factors in AML

  2021cites this paper
• Role of GATA2 in Human NK Cell Development.

  2021cites this paper
• CEBPA Mutations in 4708 Patients with Acute Myeloid Leukemia - Differential Impact of bZIP and TAD Mutations on Outcome.

  2021cites this paper
• Frequency and clinical impact of WT1 mutations in the context of CEBPA-mutated acute myeloid leukemia

  2021cites this paper
• Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia

  2020cites this paper
• Detection of measurable residual disease may better predict outcomes than mutations based on next‐generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA

  2020cites this paper
• Acute Myeloid Leukemia

  2020cites this paper
• Germline Mutations with Predisposition to Myeloid Neoplasms

  2020cites this paper
• CCAAT enhancer binding protein alpha (CEBPA) biallelic acute myeloid leukaemia: cooperating lesions, molecular mechanisms and clinical relevance

  2020influential citation
• Companion gene mutations and their clinical significance in AML with double mutant CEBPA

  2019cites this paper
• Mutation profiling of 16 candidate genes in de novo acute myeloid leukemia patients

  2019cites this paper
• Reclassification of Acute Myeloid Leukemia According to the 2016 WHO Classification

  2019cites this paper
• Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations

  2019cites this paper
• Emerging molecular predictive and prognostic factors in acute myeloid leukemia

  2018influential citation
• Myeloid Neoplasm With Germline Predisposition: A 2016 Update for Pathologists.

  2018cites this paper
• Concomitant WT1 mutations predict poor prognosis in acute myeloid leukemia patients with double mutant CEBPA

  2018influential citation
• Genetic Landscape of Acute Myeloid Leukemia Interrogated by Next-generation Sequencing: A Large Cancer Center Experience.

  2018cites this paper
• Mutational spectrum of acute myeloid leukemia patients with double CEBPA mutations based on next-generation sequencing and its prognostic significance

  2018influential citation
• Updates on Old and Weary Haematopoiesis

  2018cites this paper
• GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia

  2018cites this paper
• Clinical implications of molecular markers in acute myeloid leukemia

  2018cites this paper
• Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy

  2018cites this paper
• Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA.

  2018cites this paper
• Heritable RUNX1 and GATA2 Mutation with a Very Rare Gene Variant Associated with AML-MDS: A Case Report and Review of Literature

  2018cites this paper
• The GATA factor revolution in hematology.

  2017cites this paper
• Molecular Mutations and Their Cooccurrences in Cytogenetically Normal Acute Myeloid Leukemia

  2017cites this paper
• Familial CEBPA-mutated acute myeloid leukemia.

  2017cites this paper
• Variable outcome and methylation status according to CEBPA mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatment

  2017cites this paper
• Myelodysplastic syndromes and acute leukemia with genetic predispositions: a new challenge for hematologists

  2016cites this paper
• Studies to Investigate Epigenetic Factors in Acute Myeloid Leukaemia

  2016influential citation
• Myelodysplastic features in a patient with germline CEBPA-mutant acute myeloid leukaemia

  2016cites this paper
• Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors.

  2016cites this paper
• Genomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid Leukemia

  2015cites this paper
• Next Generation Sequencing of Acute Myeloid Leukemia: Influencing Prognosis

  2015cites this paper
• Haematopoietic and immune defects associated with GATA2 mutation

  2015cites this paper
• The Impact of Molecular Genetic in Acute Myeloid Leukemias

  2015cites this paper
• Acute Myeloid Leukemia With Recurrent Genetic Abnormalities Other Than Translocations.

  2015cites this paper
• Sialidase inhibition to increase platelet counts: A new treatment option for thrombocytopenia

  2015cites this paper
• Classification of CEBPA mutated acute myeloid leukemia by GATA2 mutations

  2015cites this paper
• ASXL1 mutations define a subgroup of patients with acute myeloid leukemia with distinct gene expression profile and poor prognosis: a meta-analysis of 3311 adult patients with acute myeloid leukemia

  2015cites this paper
• Sialidase inhibition to increase platelet counts: A new treatment option for thrombocytopenia

  2015cites this paper
• Disease evolution and outcomes in familial AML with germline CEBPA mutations.

  2015cites this paper
• Spectrum of myeloid neoplasms and immune deficiency associated with germline GATA2 mutations

  2015cites this paper
• MYELOID NEOPLASIA Disease evolution and outcomes in familial AML with germline CEBPA mutations

  2015cites this paper
• Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics.

  2014cites this paper
• Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing

  2014cites this paper
• Contribution of the GATA2 transcription factor to the development and progression of myeloid disorders

  2014cites this paper
• Heritable GATA2 mutations associated with familial AML-MDS: a case report and review of literature

  2014cites this paper
• Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.

  2014cites this paper
• The Use of Molecular Genetics to Refine Prognosis in Acute Myeloid Leukemia

  2014cites this paper
• The role of different genetic subtypes of CEBPA mutated AML

  2014cites this paper
• The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias

  2013cites this paper
• Acute myeloid leukemia

  2004cites this paper